Advertisement

Search Results

Advertisement



Article Topics

Your search for Krishnansu Tewari matches 6 pages

Showing 1 - 6


gynecologic cancers

Final Overall Survival Results of GOG 240 Trial Adding Bevacizumab to Chemotherapy in Advanced Cervical Cancer

As reported in The Lancet by Tewari et al, the final overall survival results of the phase III Gynecologic Oncology Group (GOG) 240 trial show continued benefit of the addition of bevacizumab (Avastin) to chemotherapy in patients with metastatic, persistent, or recurrent cervical carcinoma. Study...

gynecologic cancers

Moore Scoring System Helps Identify Women With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab

Previously published reports from the randomized phase III Gynecologic Oncology Group (GOG) protocol 240 clinical trial showed that adding bevacizumab (Avastin) to a chemotherapy regimen of paclitaxel plus cisplatin or topotecan significantly increased overall survival and progression-free survival ...

gynecologic cancers
gynecologic cancers

Experimental Immunotherapy Delays Recurrence for Stage III and IV Ovarian Cancers

According to a phase II study presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, an experimental immunotherapy is in the works that can target an individual woman’s ovarian tumor and extend the time period between initial treatment and the cancer’s...

gynecologic cancers

Adding Bevacizumab to Chemotherapy Improves Survival in Advanced Cervical Cancer

Retreatment with cisplatin has reduced effectiveness in patients with recurrent cervical cancer who have received cisplatin with radiation therapy. In a 2×2 factorial phase III trial reported in The New England Journal of Medicine, Tewari et al compared cisplatin/paclitaxel vs nonplatinum...

gynecologic cancers

ASCO 2013: Adding Bevacizumab to Chemotherapy Significantly Improves Response Rates and Survival in Women with Advanced Cervical Cancer

Adding bevacizumab (Avastin) to chemotherapy regimens with or without a platinum drug improved outcomes for women with metastatic or relapsed cervical cancer treated in a randomized phase III study. Presenting the results at the 2013 ASCO Annual Meeting (Abstract 3), lead author Krishnansu Sujata...

gynecologic cancers
gynecologic cancers

Bevacizumab Significantly Improves Survival for Patients with Recurrent and Metastatic Cervical Cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial. The...

Advertisement

Advertisement



;
Advertisement